Background
Methods
Objective
Inclusion criteria
Search strategies
Outcomes selected
Data extraction and evaluation of methodological quality of the studies
Statistical methods
Results
Literature search
Efficacy and safety of pharmaceutical interventions
Folic acid (FA) | |||
---|---|---|---|
Reference
|
Participants and Follow-Up Period
|
Methods
|
Interventions
|
Brown 1984 [21] | N = 2 brothers, 10.5 and 18.8 years. Setting: in-patients. FUP: 16 days | R, CO, DB. AASG: no; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 1,6 mg/kg intravenous vs Placebo |
Brown 1986 [22] | N = 5 males, 8 to 26 years. 3 autism FUP: 9 months | R, CO, DB. AASG: unclear; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 250 mg/day vs Placebo |
Carpenter 1983 [23] | N = 4 males, 2 to 10 years. IQs: 45 to 50. 2 autistic behaviour. FUP: 6 months | NR, CO, DB. AASG: no; AAC: unclear; AB: unclear; IDAA: unclear; FSR: unclear. | FA 10 mg/day vs Placebo |
Fisch 1988 [24] | N = 6 males, 3.5 to 15 years. 3 autistic, 3 mental retardation only (borderline to severe). FUP: 12 months | R, CO, DB, SA. AASG: unclear; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 10 mg/day vs Placebo |
Froster-Iskenius 1986 [29] | N = 10 males, 15 to 54 years. IQ: 21 to 60. FUP: 4 months | R, P, DB. AASG: unclear; AAC: unclear; AB: no; IDAA: yes; FSR: yes. | FA 10 mg/day vs 0.0015 mg of folic acid/day, 2 months and 2 months with folic acid, 10 mg/day |
Gillberg 1986 [30] | N = 4 males, 6 to 14 years. IQ: 39 to 64. All autism, 3 epilepsy. FUP: 9 months | NR, CO, DB, SA. AASG: no; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 5 mg/day vs Placebo |
Hagerman 1986 [25] | N = 25 males, 1 to 31 years. IQ: 39 to 82. Many of the younger ones in special education program with language and occupational therapy. Many adults use phenothiazines. FUP: 12 months | R, CO, DB, SA. AASG: yes; AAC: unclear; AB: yes; IDAA: yes; FSR: yes. | FA 10 mg/day vs Placebo |
Madison 1986 [26] | N = 3 males, 3, 8 and 12 years old. Moderate mental retardation. FUP: 11 weeks | NR, DB. AASG: no; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | No drug-no placebo (20 days). Placebo (13-45 days). Folic acid 10 mg/day (10-43 days) |
Rosenblatt 1985 [28] | N = 2 monozygous male twins, 14 years old, mentally retarded. FU: 12 months | NR, CO. AASG: no; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 5 mg/day vs Placebo |
Strom 1992 [27] | N = 21 males, 2-22 years, mean 8.3 years. FUP: 24 weeks | R, CO, DB, SA. AASG: unclear; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | FA 15 mg/day vs Placebo |
Ampakine compound CX516
| |||
Berry-Kravis 2006 [14] | N = 49. 11 female, 18-49 years. IQ: 36 to75, mean 43; 12 ≥50. Autism 21, spectrum: 4. 27 on psychoactive medication. FUP: 4 weeks | Phase II, R, P, DB, SA. AASG: yes; AAC: yes; AB: yes; IDAA: yes; FSR: yes. | Ampakine compound CX516 600-900 mg/day vs Placebo |
Dextroamphetamine Methylphenidate
| |||
Hagerman 1988 [5] | N = 15, 2 female. 3.8-11.8 years. IQ: 29 to 77 (3 IQ >70). All attentional problems. 40% on stimulants. FUP: 3 weeks | R, CO, DB, SA. AASG: unclear; AAC: unclear; AB: yes; IDAA: yes; FSR: yes. | Dextroamphetamine 2 mg/kg/day vs Methylphenidate 0.6 mg/kg/day vs Placebo |
L-Acetylcarnitine
| |||
Torrioli 1999 [32] | N = 20 males, 6-13 years. IQ:30 to 69 Hyperactive behaviour. FUP: 12 months | R, P, DB, SA. AASG: unclear; AAC: unclear; AB: unclear; IDAA: unclear; FSR: yes. | L-Acetylcarnitine 100 mg/kg/day vs Placebo |
Torrioli 2008 [13] | N = 63 males, 6-13 years, all with Attention Deficit Hyperactivity Disorder. All extra care and stimulation at school and home, and visits by neuropsychiatrists. FUP: 12 months | Phase II, R, P, DB, SA. AASG: unclear; AAC: unclear; AB: unclear; IDAA: yes; FSR: yes. | L-Acetylcarnitine 20-50 mg/kg/day vs Placebo |
Reference
|
Measures of interest: assessment method
|
Main Results
|
---|---|---|
Brown 1984 [21] | Psychological: Stanford-Binet, Peabody Picture Vocabulary Test Revised (PPVTR) Leither International Performance Scale of non-verbal performance. Scoring by researchers and parents for eye contact, appropriate social smiling, communicative speech and hyperventilating. | Stanford Binet IQ scores did not change significantly. PPVT-R scores appeared unrelated to folic acid treatment. Leither test of non-verbal performance showed improvement in one subject, from 3.0 to 5.6, but not in the other (no more details in article). Statistical testing not presented. Safety: no side effects. |
Brown 1986 [22] | Leiter or Wechsler IQ tests. Autistic Descriptors Checklist (ADC): parental reporting rating checklist. Alpern-Ball test. | Changes of performance ratings not correlated with treatment. Pooled data not provided, only person by person. Statistical testing not presented. Safety: nothing reported. |
Carpenter 1983 [23] | Psychological, speech and language, and psychiatric evaluations but not specified. | No measurable improvement in speech, language or intellectual abilities were found during therapy. Numeric data not provided. Statistical testing not presented. Safety: nothing reported. Note: Data from abstract. |
Fisch 1988 [24] | Autistic Descriptors Checklist (ADC). Vineland Adaptative Behaviour Scale (VABS). | No statistically significant improvements in periods of folic acid treatment, neither in prepubescent nor in adolescent patients. Pooled data not provided, only person by person. Safety: nothing reported. |
Froster-Iskenius 1986 [29] | Coloured Progressive Matrices test (CPM). Test for fine motor co-ordination, concentration and comprehension. | No improvement in concentration, fine motor co-ordination or comprehension in adults, but may have some effect in children. Pooled data not provided, only person by person. Statistical testing not presented. Safety: nothing reported. |
Gillberg 1986 [30] | Autism Behaviour Checklist (ABC) and other checklist questionnaires pertaining to autism developed by authors. Parents "unstructured" diaries on child overall behaviour and language skills. | Mean ABC scores did not differ in a statistically significant way between placebo and folic acid periods. Numerical detailed information not provided. Safety: nothing reported. |
Hagerman 1986 [25] | Speech and language testing: Peabody Picture Vocabulary Test (PPVT), Test of Language Development (TOLD) and an apraxia battery. Psychological testing: Yale Revised Developmental Schedules, Stanford-Binet, Leiter International Scale. Behavioural assessments: Autism Behavior Checklist (ABC) of the Autism Screening Instrument for Educational Planning (ASIEP) and the Childhood Autism Rating Scale (CARS). | No statistical differences (Wilcoson Rank Sum Test) between placebo and folic acid in: change in IQ, language (PPVT, TOLD, apraxia battery) behavioural areas, CARS, ABC. Psychological testing: IQ scores statistically significant improvement in prepuberal males while being treated with folic acid (one tailed p = 0.014; two tailed p = 0.028). Safety: nothing reported. |
Madison 1986 [26] | Memory skills: Automated Device for the Assessment of Memory (ADAM); Verbal recall of objects and number series. Compliance and behavioural appropriateness. | No evident change in memory skills, compliance and behavioural appropriateness during treatment phase. Pooled data not provided, only person by person. Statistical testing not presented. Safety: nothing reported. |
Rosenblatt 1985 [28] | Wechsler Intelligence Scale for Children-Revised (WISC-R) Peabody Picture Vocabulary Test Form M (PPVT), Goodenough-Harris Drawing Test (G-H), Rey Children's Word List, Token Test of Auditory Comprehension, Producing Names on Confrontation (test 8 of Clinical Evaluation of Language functioning (CELF), Boston Naming Test, Developmental Test of Visual-Motor integration (DTVMI), Wide Range Achievement Test (WRAT), reading Comprehension (Barnell Loft Multiple Skills Series Al) and Domino Pattern Counting Task. Parent's Questionnaire, Teacher Behavior Checklist and a Checklist of Problem Behaviors. | |
Strom 1992 [27] | Cognitive function and behavioural level: Vineland Adaptive Behavioral Scales, Peabody Picture Vocabulary Test-Revised (PPVT-R), Conners' Parent and Teaching Rating Scales, the ADD-H: Comprehensive Teacher's Rating Scales (ACTeRS), and a questionnaire designed by the researchers | No statistically significant differences between the folic acid and placebo phases of the study in any outcome measurement instrument: Vineland (51.0 vs 50.9); PPVT-R (55.4 vs 59.2), Conners' (15.5 vs 13.4). Safety: minor side effects (transient problems with diarrhea, sleep delays, mood swings. |
Ampakine compound CX516 | ||
---|---|---|
Reference
|
Measures of interest: assessment method
|
Main Results
|
Berry-Kravis 2006 [14] | Primary outcome, memory domain: Visual Memory and Visual Sequential Memory Subtests of the Test of Visual--Perceptual Skills (TVPS), the Memory for Words Subtest of the Woodcock-Johnson Tests of Cognitive Ability--Revised and the Repeatable Battery for the Assessment of the Neuropsychological Status (RBANS). Secondary outcome measures. Attention/Executive Function Domain: SNAP IV. Language Domain: Peabody Picture Vocabulary Test-III, Forms A and B (PPVT-III) or the Clinical Evaluation of Language Fundamentals-3 (CELF-3). Behavioral Domain: Autism Diagnostic Observation Scale (ADOS), the Gilliam Autism Rating Scale (GARS), the Childhood Autism Rating Scale (CARS), a clinician-rated scale to evaluate modification of autistic features, the ABC-C, and the behaviour component of CGI - Improvement (CGI-I) and VAS. Clinical Cognitive Improvement Measures: VAS (caregiver rated) for cognition and the subject's chosen task (described above) and CGI-I (clinician rated) for cognition and the task. Adverse events: Aberrant Behavior Checklist - Community Edition (ABC-C). | Wilkoson rank-sum test performed. No significant improvement in memory, the primary outcome measure, or in secondary measures of language, attention/executive function, behaviour, and overall functioning in CX516-treated subjects compared to placebo. There were minimal side effects, no significant changes in safety parameters, and no serious adverse events. There was a 12.5% frequency of allergic rash in the CX516 group and 1 subject developed a substantial rash. |
Dextroamphetamine Methylphenidate
| ||
Reference
|
Measures of interest: assessment method
|
Main Results
|
Hagerman 1988 [5] | Conners' Abbreviated Parent-Teacher Questionnaire. ADDH: Comprehensive Teacher Rating Scale (ACTeRS). Behavioural observation. Measure of movement: Large scale integrated sensor actometer (LSI). Delay task. Vigilance task. | Paired t tests performed. Compare to placebo clinical response in two thirds of patients, but no statistically significant difference between amphetamine and placebo for any of the ADHD measures, except for the improvement seen on the ACTeRS scale completed by the teacher. Social skills factor and improvements in attention significantly better with methylphenidate (mostly in mildly retarded persons) but not with amphetamine. Safety: significantly more side effects while taking amphetamine, mainly mood lability and irritability. |
L-Acetylcarnitine
| ||
Reference
|
Measures of interest: assessment method
|
Main Results
|
Torrioli 1999 [32] | Wechsler Intelligence Scale for Children-Revised (WISC-R); the Bender Gestalt test; and the Conners' Abbreviated Parent-Teacher Questionnaire. | Non-parametric Wilcoson independent-sample test performed. No statistically significant difference between L-Acetylcarnitine and placebo in Wechsler Scale and Bender Gestalt tests and Conners' questionnaire completed by teachers. The Conners' Abbreviated Parent questionnaire showed a significant reduction (P = 0.0065) of hyperactive behaviour at one year in the LAC-treated subjects. Safety: no side effects noted in LAC group. |
Torrioli 2008 [13] | Conners' Global Index-Parents (CGI-P) and Conners' Global Index-Teachers (CGI-T). Vineland Adaptive Behavior Scales-Survey Form (VABS) to evaluate adaptive behaviour, four domains: communication, daily living skills, socialization, and motor skills. Wechsler Intelligence Scale for Children-Revised (WISC-R). Side effects. | T tests and repeated measures multivariate analysis using the general linear model were performed. Statistically significant stronger reduction of hyperactivity and improvement of social behaviour in patients treated with LAC, compared with the placebo group, in CGI-P y VABS. Both groups improved their behaviour, showing that psychosocial intervention has a significant therapeutic effect. Safety: no side effects in LAC group. |